Zobrazeno 1 - 10
of 3 503
pro vyhledávání: '"C de Bruin"'
Autor:
Sebastijan Hobor, Maise Al Bakir, Crispin T. Hiley, Marcin Skrzypski, Alexander M. Frankell, Bjorn Bakker, Thomas B. K. Watkins, Aleksandra Markovets, Jonathan R. Dry, Andrew P. Brown, Jasper van der Aart, Hilda van den Bos, Diana Spierings, Dahmane Oukrif, Marco Novelli, Turja Chakrabarti, Adam H. Rabinowitz, Laila Ait Hassou, Saskia Litière, D. Lucas Kerr, Lisa Tan, Gavin Kelly, David A. Moore, Matthew J. Renshaw, Subramanian Venkatesan, William Hill, Ariana Huebner, Carlos Martínez-Ruiz, James R. M. Black, Wei Wu, Mihaela Angelova, Nicholas McGranahan, Julian Downward, Juliann Chmielecki, Carl Barrett, Kevin Litchfield, Su Kit Chew, Collin M. Blakely, Elza C. de Bruin, Floris Foijer, Karen H. Vousden, Trever G. Bivona, TRACERx consortium, Robert E. Hynds, Nnennaya Kanu, Simone Zaccaria, Eva Grönroos, Charles Swanton
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-21 (2024)
Abstract The phenomenon of mixed/heterogenous treatment responses to cancer therapies within an individual patient presents a challenging clinical scenario. Furthermore, the molecular basis of mixed intra-patient tumor responses remains unclear. Here
Externí odkaz:
https://doaj.org/article/a58c4b29e1d8491b8078212067633916
Publikováno v:
Nederlands archief voor kerkgeschiedenis / Dutch Review of Church History, 1989 Jan 01. 69(1), 1-2.
Externí odkaz:
https://www.jstor.org/stable/24009190
Autor:
van Woerden, A. V. N.
Publikováno v:
Nederlands archief voor kerkgeschiedenis / Dutch Review of Church History, 1989 Jan 01. 69(1), 3-11.
Externí odkaz:
https://www.jstor.org/stable/24009191
Autor:
Lorna Hopcroft, Eleanor M. Wigmore, Stuart C. Williamson, Susana Ros, Cath Eberlein, Jennifer I. Moss, Jelena Urosevic, Larissa S. Carnevalli, Sara Talbot, Lauren Bradshaw, Catherine Blaker, Sreeharsha Gunda, Venetia Owenson, Scott Hoffmann, Daniel Sutton, Stewart Jones, Richard J. A. Goodwin, Brandon S. Willis, Claire Rooney, Elza C. de Bruin, Simon T. Barry
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-14 (2023)
Abstract Combining the selective AKT inhibitor, capivasertib, and SERD, fulvestrant improved PFS in a Phase III clinical trial (CAPItello-291), treating HR+ breast cancer patients following aromatase inhibitors, with or without CDK4/6 inhibitors. How
Externí odkaz:
https://doaj.org/article/216706db2e6b4b6eae15d98244910c27
Autor:
E. Maes
Publikováno v:
BMGN: Low Countries Historical Review, Vol 113, Iss 3 (1998)
Externí odkaz:
https://doaj.org/article/ac2046e1fd744533b1751c2c6d93a26c
Autor:
Metzger, Bruce M.
Publikováno v:
Journal of Biblical Literature, 1973 Dec 01. 92(4), 634-636.
Externí odkaz:
https://www.jstor.org/stable/3263157
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Lorna Hopcroft, Eleanor M. Wigmore, Stuart C. Williamson, Susana Ros, Cath Eberlein, Jennifer I. Moss, Jelena Urosevic, Larissa S. Carnevalli, Sara Talbot, Lauren Bradshaw, Catherine Blaker, Sreeharsha Gunda, Venetia Owenson, Scott Hoffmann, Daniel Sutton, Stewart Jones, Richard J. A. Goodwin, Brandon S. Willis, Claire Rooney, Elza C. de Bruin, Simon T. Barry
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/597341a4bba64230b85546c506522cc0
Autor:
Tereza Vaclova, Atanu Chakraborty, James Sherwood, Sarah Ross, Danielle Carroll, J. Carl Barrett, Julian Downward, Elza C. de Bruin
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract The development of covalent inhibitors against KRAS G12C represents a major milestone in treatment of RAS-driven cancers, especially in non-small cell lung cancer (NSCLC), where KRAS G12C is one of the most common oncogenic driver. Here we i
Externí odkaz:
https://doaj.org/article/80183fd1fcb54089bce08329d47a9691
Autor:
Ricardo J. M. G. E. Brandwijk, Marloes A. H. M. Michels, Mara van Rossum, Aline H. de Nooijer, Per H. Nilsson, Wieke C. C. de Bruin, Erik J. M. Toonen
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundThe complement system is an essential component of our innate defense and plays a vital role in the pathogenesis of many diseases. Assessment of complement activation is critical in monitoring both disease progression and response to therap
Externí odkaz:
https://doaj.org/article/a2887dc7c436477cbccef38daa8048a3